Latest news for Accustem Sciences (OTC:ACUT) Stock

Accustem Sciences Inc is a life sciences company that focuses on enhancing cancer patient outcomes through diagnostic, pharmaceutical, and medical device products. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services. Operations span New York, NY, and London, UK.

Long Ideas

News

Penny Stocks

Insider Trades

Markets

Trading Ideas

ACUT

AUGG

BJDX

RYES

US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

4 Stocks Under $2 Insiders Are Aggressively Buying

ACCUSTEM SCIENCES INC by Accustem Sciences Inc.

Accustem Sciences Inc

ACUTUS MEDICAL INC by Acutus Medical Inc.

Acutus Medical Inc

<p><strong>Performance Food Gr's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFGC#NYSE">PFGC</a>) short percent of float has risen 10.41% since its last report. The company recently reported that it has <strong>2.66 million shares sold short</strong>, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.19 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Performance Food Gr Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735845320_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Performance Food Gr has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Performance Food Gr's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Performance Food Gr's peer group average for short interest as a percentage of float is 4.45%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

PFGC

Looking Into Performance Food Gr's Recent Short Interest

<p><strong>SEALSQ's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NYSE">LAES</a>) short percent of float has risen 41.61% since its last report. The company recently reported that it has <strong>9.00 million shares sold short</strong>, which is 12.66% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.0 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>SEALSQ Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735845315_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for SEALSQ has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing SEALSQ's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, SEALSQ's peer group average for short interest as a percentage of float is 10.10%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


LAES

Looking Into SEALSQ's Recent Short Interest

<p><strong>Builders FirstSource's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) short percent of float has risen 22.67% since its last report. The company recently reported that it has <strong>2.59 million shares sold short</strong>, which is 3.03% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 2.46 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Builders FirstSource Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735845310_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Builders FirstSource has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Builders FirstSource's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Builders FirstSource's peer group average for short interest as a percentage of float is 3.48%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


BLDR

How Is The Market Feeling About Builders FirstSource?

<p><strong>Fubotv Inc&nbsp;</strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>) shares are moving higher Thursday. After becoming oversold, the recent downtrend may have ended. A new uptrend may be forming.</p>
<p>Our team of technical analysts has made it our <strong>Stock of the Day.</strong></p>
<p>The term oversold refers to a stock's momentum. Momentum is a measurement of the distance it has moved between time period A and time period B.</p>
<p>There are dozens if not hundreds of ways to measure momentum. These are called momentum indicators or oscillators.</p>
<p>Many new traders put a large number of these indicators on their charts. They think that more is better and they will have a good chance of identifying low-risk trading ideas.</p>
<p>But it may make sense to only use two or three of these indicators, master them and learn their nuances. For example, the lower part of the chart is the Relative Strength Index (RSI) momentum indicator.</p>
<p>Indicators usually have default settings. The default of the RSI is to measure the amount a stock has moved over 14 time periods.</p>
<p><figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1489" height="816" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02140305/1-1024x561.png" alt="" class="wp-image-715876" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02140305/1-1024x561.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02140305/1-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02140305/1-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/02140305/1.png 1489w" sizes="(max-width: 1489px) 100vw, 1489px" /></figure></p>
<p><strong>Read Also:</strong> <a href="https://www.benzinga.com/24/12/42668117/spanish-language-showdown-fubotv-battles-televisaunivision-for-fair-pricing">Fubotv Battles TelevisaUnivision for Fair Pricing In Spanish-Language Showdown</a></p>
<p>Between time period A and time period B, 14 days later, a stock may make a huge move up or down and then reverse and end up at the same price the measurement started at. Because RSI measures the difference between the prices between A and B, it will not account for these large movements.</p>
<p>This means the indicator may show a stock's momentum to be neutral when it is actually overbought or oversold.</p>
<p>RSI also has thresholds to identify overbought or oversold conditions. The default threshold for being overbought is exceeding the 70 level on the right side of the chart. The default setting for being oversold is when RSI drops to 30 or below.</p>
<p>Sometimes, the default settings can provide accurate signals. But sometimes traders can use different settings to obtain better results.</p>
<p>As you can see on the chart, when the RSI for Fubotv drops to 35, it is oversold. Since May each time this happened was a good time to buy. The RSI never reached 30. If a trader used the default settings, they would have missed these trades.</p>
<p>The &#8220;personality&#8221; of Fubotv is to be oversold when RSI reaches 35.</p>
<p>Instead of using a large number of momentum indicators, a trader may have better results if they only use a few and learn their nuances. The chart of <a href="https://www.benzinga.com/quote/FUBO">Fubotv</a> is a good illustration of this.</p>
<p><strong>Read Next:</strong> <br />    • <a href="https://www.benzinga.com/markets/equities/25/01/42758021/roaring-kitty-keith-gill-sparks-speculation-with-rick-james-themed-post-on-x-gamestop-chewy-shares-in-focus">&#8216;Roaring Kitty&#8217; Keith Gill Sparks Speculation With Rick James-Themed Post On X: GameStop, Chewy Shares In Focus — Unity Software Pops 12%</a></p>
<p><em>Photo: Courtesy of FuboTv.</em></p>


Entertainment

Technicals

Media

FUBO

Stock Of The Day: Is The Fubotv Sell-Off Over?

<p>U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 300 points on Thursday.</p>
<p>The Dow traded down 0.79% to 42,208.88 while the NASDAQ fell 0.89% to 19,138.50. The S&amp;P 500 also fell, dropping, 0.79% to 5,834.99.</p>
<p>Check This Out: <a href="https://www.benzinga.com/25/01/42763645/how-to-earn-500-a-month-from-acuity-brands-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Acuity Brands Stock Ahead Of Q1 Earnings</a></p>
<p><strong>Leading and Lagging Sectors</strong><br /><br />Energy shares rose by 1% on Thursday.</p>
<p>In trading on Thursday, real estate shares fell by 1.7%.</p>
<p><strong>Top Headline</strong></p>
<p>U.S. construction spending unexpectedly stalled month-over-month to an annual rate of $2,153 billion in November compared to a revised 0.5% gain in October and missing market estimates of a 0.3% rise.</p>
<p><strong>Equities Trading UP</strong><br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<ul>
<li><strong>Carmell Corporation </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares shot up 187% to $0.80 after the company announced an agreement to acquire Elevai Skincare.</li>
<li>Shares of <strong>N2OFF, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NITO#NASDAQ">NITO</a>)got a boost, surging 335% to $1.08 after the company announced its joint venture with Soltera Renewable Energy obtained approval for a 111 MWp solar PV project in Meltz, Germany.</li>
<li><strong>Unity Software Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) shares were also up, gaining 7% to $24.05 on the heels of a new post from meme stock trader Keith Gill, also known as &#8220;Roaring Kitty." Gill's latest post on X has sparked speculation that the trader could be planning to invest in shares of Unity Software.</li>
</ul>
<p><strong>Equities Trading DOWN</strong></p>
<ul>
<li><strong>Neumora Therapeutics, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) shares dropped 81% to $2.00 after the company announced its Phase 3 KOASTAL study did not demonstrate statistically significant improvement on its primary endpoint.</li>
<li>Shares of <strong>Kodiak Sciences Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOD#NASDAQ">KOD</a>) were down 12% to $8.78.</li>
<li><strong>Tesla, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) was down, falling 7% to $377.36 following fourth-quarter <a href="https://www.benzinga.com/pressreleases/25/01/b42764219/tesla-fourth-quarter-2024-production-deliveries-deployments">production and delivery figure</a>s. Tesla said it produced 459,445 vehicles in the fourth quarter and delivered 495,570 vehicles. For comparison, Tesla reported production of 494,989 vehicles and 484,507 deliveries in the fourth quarter of 2023.</li>
</ul>
<p><strong>Commodities</strong><br /><br />In commodity news, oil traded up 2% to $73.15 while gold traded up 1% at $2,667.20.</p>
<p>Silver traded up 2.2% to $29.900 on Thursday, while copper fell 0.1% to $4.0250.</p>
<p><strong>Euro zone</strong></p>
<p>European shares were higher today. The eurozone's STOXX 600 rose 0.60%, Germany's DAX 40 gained 0.58% and France's CAC 40 rose 0.18%. Spain's IBEX 35 Index rose 0.71%, while London's FTSE 100 rose 1.07%.</p>
<p><strong>Asia Pacific Markets</strong></p>
<p>Asian markets closed mixed on Thursday, with China's Shanghai Composite Index falling 2.66%, Hong Kong's Hang Seng Index dipping 2.18% and India's BSE Sensex gaining 1.83%.</p>
<p><strong>Economics</strong></p>
<ul>
<li>U.S. initial jobless claims fell by 9,000 from the previous week to a reading of 211,000 in the final week of 2024, and versus market estimates of 222,000.</li>
<li>The S&amp;P Global manufacturing PMI declined to 49.4 in December compared to 49.7 in the prior month, and versus a revised preliminary reading of 48.3.</li>
<li>U.S. construction spending unexpectedly stalled month-over-month to an annual rate of $2,153 billion in November compared to a revised 0.5% gain in October and missing market estimates of a 0.3% rise.</li>
</ul>
<p><strong>Now Read This: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/price-target/25/01/42762297/this-analyst-with-85-accuracy-rate-sees-around-10-upside-in-alphabet-here-are-5-stock-picks-for-2024-from-wall-streets-most-accurate-analysts">This Analyst With 85% Accuracy Rate Sees Around 10% Upside In Alphabet &#8211; Here Are 5 Stock Picks For 2024 From Wall Street&#8217;s Most Accurate Analysts</a></strong></li>
</ul>


Equities

Eurozone

Commodities

Intraday Update

CTCX

NITO

NMRA

TSLA

Crude Oil Surges 2%; Tesla Shares Plummet

<p>During the last three months, 18 analysts shared their evaluations of Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">9</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.38, a high estimate of $60.00, and a low estimate of $40.00. This current average reflects an increase of 1.75% from the previous average price target of $48.53. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844451_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Comcast is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alan Gould</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Benjamin Swinburne</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>David Joyce</td>
<td>Seaport Global</td>
<td>Announces</td>
<td>Buy</td>
<td>$46.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Barton Crockett</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Kannan Venkateshwar</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Steven Cahall</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$46.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Brandon Nispel</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Jeffrey Wlodarczak</td>
<td>Pivotal Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Gregory Williams</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$48.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Bryan Kraft</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$50.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Tim Nollen</td>
<td>Macquarie</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$48.00</td>
<td>$47.75</td>
</tr>
<tr>
<td>Matthew Harrigan</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$55.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Maher Yaghi</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$47.75</td>
<td>$47.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Comcast. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Comcast compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Comcast's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CMCSA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Comcast analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Comcast</h2>
<p>Comcast is made up of three parts. The core cable business owns networks capable of providing television, internet access, and phone services to 63 million US homes and businesses, or nearly half of the country. About 50% of the locations in this territory subscribe to at least one Comcast service. Comcast acquired NBCUniversal from General Electric in 2011. NBCU owns several cable networks, including CNBC, MSNBC, and USA, the NBC network, the Peacock streaming platform, several local NBC affiliates, Universal Studios, and several theme parks. Sky, acquired in 2018, is a large television provider in the UK and has invested heavily in proprietary content to build this position. Sky is also a large pay-television provider in Italy and has a presence in Germany and Austria.</p>
<h3>A Deep Dive into Comcast's Financials</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Comcast showcased positive performance, achieving a revenue growth rate of <strong>6.49%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Comcast's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>11.32%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Comcast's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>4.29%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.36%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Comcast's debt-to-equity ratio is below the industry average. With a ratio of <b>1.18</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

CMCSA

Assessing Comcast: Insights From 18 Financial Analysts

<p>Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on SoFi Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOFI#NASDAQ">SOFI</a>) in the last three months.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $11.85, along with a high estimate of $16.00 and a low estimate of $7.00. This upward trend is evident, with the current average reflecting a 20.8% increase from the previous average price target of $9.81.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844441_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive SoFi Techs is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timothy Switzer</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Underperform</td>
<td>$8.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Jeffrey Adelson</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$13.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Mihir Bhatia</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Underperform</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Reginald Smith</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Tim Chiodo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$10.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Michael Ng</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$8.50</td>
<td>$7.50</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>John Hecht</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Dan Dolev</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Timothy Switzer</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to SoFi Techs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of SoFi Techs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of SoFi Techs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into SoFi Techs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SOFI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on SoFi Techs analyst ratings.</strong></a></p>
<h2>Delving into SoFi Techs's Background</h2>
<p>SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.</p>
<h3>Unraveling the Financial Story of SoFi Techs</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> SoFi Techs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>29.15%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.</p>
<p><strong>Net Margin:</strong> SoFi Techs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>8.76%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.01%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.18%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> SoFi Techs's debt-to-equity ratio is below the industry average. With a ratio of <b>0.54</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SOFI

Analyst Expectations For SoFi Techs's Future

<p>During the last three months, 4 analysts shared their evaluations of COPT Defense (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDP#NYSE">CDP</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $35.5, with a high estimate of $38.00 and a low estimate of $33.00. Observing a 5.97% increase, the current average has risen from the previous average price target of $33.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844434_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>A comprehensive examination of how financial experts perceive COPT Defense is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Lewis</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$33.00</td>
<td>$31.00</td>
</tr>
<tr>
<td>Thomas Catherwood</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$38.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$33.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to COPT Defense. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of COPT Defense compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for COPT Defense's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of COPT Defense's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CDP/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on COPT Defense analyst ratings.</strong></a></p>
<h2>Delving into COPT Defense's Background</h2>
<p>COPT Defense Properties is a real estate investment trust that acquires, manages, and leases office and data center properties throughout the U.S. The majority of the company's real estate portfolio is composed of office buildings in the Baltimore-Washington Corridor and Northern Virginia area. COPT derives nearly all of its income in the form of rental revenue from tenants. Most of the company's revenue comes from the leasing of properties to U.S. Government agencies and its contractors in the national security, defense, and IT sectors, such as Northrop Grumman and Boeing. Regional offices in urban submarkets make also make up a sizable percentage of COPT's total square footage.</p>
<h3>COPT Defense: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.</p>
<p><strong>Revenue Growth:</strong> COPT Defense displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>12.26%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> COPT Defense's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>19.0%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> COPT Defense's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>2.42%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> COPT Defense's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.85%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> COPT Defense's debt-to-equity ratio surpasses industry norms, standing at <strong>1.63</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


What 4 Analyst Ratings Have To Say About COPT Defense

<p>Financial giants have made a conspicuous bearish move on Enovix. Our analysis of options history for Enovix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>) revealed 17 unusual trades.</p>
<p>Delving into the details, we found 29% of traders were bullish, while 52% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $190,289, and 13 were calls, valued at $439,740.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $32.0 for Enovix over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Enovix's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Enovix's substantial trades, within a strike price spectrum from $5.0 to $32.0 over the preceding 30 days.</p>
<h3>Enovix 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844434_0_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.05</td>
<td>$12.00</td>
<td>$63.7K</td>
<td>2.3K</td>
<td align="right">100</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$5.1</td>
<td>$4.95</td>
<td>$5.05</td>
<td>$15.00</td>
<td>$50.5K</td>
<td>431</td>
<td align="right">1</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$4.45</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$7.50</td>
<td>$46.2K</td>
<td>11.4K</td>
<td align="right">140</td>
</tr>
<tr>
<td>ENVX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.5</td>
<td>$4.35</td>
<td>$4.45</td>
<td>$14.00</td>
<td>$44.5K</td>
<td>564</td>
<td align="right">100</td>
</tr>
<tr>
<td>ENVX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$12.00</td>
<td>$40.4K</td>
<td>7.0K</td>
<td align="right">21</td>
</tr>
</tbody>
</table>
</p>
<h3>About Enovix</h3>
<p>Enovix Corp is engaged in the business of advanced silicon-anode lithium-ion battery development and production. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable the widespread utilization of renewable energy.</p>
<p>In light of the recent options history for Enovix, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Enovix's Current Market Status</h3>
<ul>
<li>With a volume of 5,586,163, the price of ENVX is up 1.2% at $11.0. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 47 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Enovix with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

ENVX

Spotlight on Enovix: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>IREN</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IREN, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 23 uncommon options trades for IREN.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 56% bullish and 43%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $93,435, and 20 are calls, for a total amount of $1,123,681.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $6.0 to $20.0 for IREN during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for IREN's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across IREN's significant trades, within a strike price range of $6.0 to $20.0, over the past month.</p>
<h3>IREN 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844429_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.11</td>
<td>$0.93</td>
<td>$1.11</td>
<td>$18.00</td>
<td>$210.3K</td>
<td>10.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$1.04</td>
<td>$0.9</td>
<td>$1.04</td>
<td>$18.00</td>
<td>$103.3K</td>
<td>10.8K</td>
<td>2.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$0.96</td>
<td>$0.9</td>
<td>$0.96</td>
<td>$18.00</td>
<td>$84.5K</td>
<td>10.8K</td>
<td>4.0K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.85</td>
<td>$0.8</td>
<td>$0.8</td>
<td>$15.00</td>
<td>$78.3K</td>
<td>23.9K</td>
<td>2.3K</td>
</tr>
<tr>
<td>IREN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.84</td>
<td>$0.71</td>
<td>$0.71</td>
<td>$15.00</td>
<td>$71.0K</td>
<td>23.9K</td>
<td>3.5K</td>
</tr>
</tbody>
</table>
</p>
<h3>About IREN</h3>
<p>IREN Ltd is engaged in data center business powering the future of Bitcoin, AI and beyond utilizing renewable energy.</p>
<h3>Where Is IREN Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,959,968, the price of IREN is up by 5.4%, reaching $10.35.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 42 days from now.</li>
</ul>
<h3>What The Experts Say On IREN</h3>
<p>4 market experts have recently issued ratings for this stock, with a consensus target price of $18.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Macquarie persists with their Outperform rating on IREN, maintaining a target price of $19.<br />
&#x2A; An analyst from JP Morgan downgraded its action to Neutral with a price target of $15.<br />
&#x2A; An analyst from B. Riley Securities persists with their Buy rating on IREN, maintaining a target price of $16.<br />
&#x2A; An analyst from Jones Trading has revised its rating downward to Buy, adjusting the price target to $22. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest IREN options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


IREN

Looking At IREN's Recent Unusual Options Activity

<p>Ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.71, a high estimate of $77.00, and a low estimate of $30.00. This upward trend is evident, with the current average reflecting a 3.69% increase from the previous average price target of $51.80.</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844427_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A comprehensive examination of how financial experts perceive Capricor Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Catherine Novack</td>
<td>Jones Trading</td>
<td>Announces</td>
<td>Buy</td>
<td>$40.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$77.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Capricor Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Capricor Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Capricor Therapeutics's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Capricor Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Capricor Therapeutics: A Closer Look</h2>
<p>Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.</p>
<h3>Unraveling the Financial Story of Capricor Therapeutics</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Capricor Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately <strong>-63.44%</strong> in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-555.2%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Capricor Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-31.48%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Capricor Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-19.14%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Capricor Therapeutics's debt-to-equity ratio is below the industry average at <strong>0.02</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CAPR

Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Salesforce</strong>.</p>
<p>Looking at options history for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) we detected 51 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 52% with bearish.</p>
<p>From the overall spotted trades, 12 are puts, for a total amount of $718,304 and 39, calls, for a total amount of $2,085,751.</p>
<h3>Expected Price Movements</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $175.0 to $500.0 for Salesforce during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Salesforce's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Salesforce's substantial trades, within a strike price spectrum from $175.0 to $500.0 over the preceding 30 days.</p>
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844424_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$85.95</td>
<td>$85.85</td>
<td>$85.95</td>
<td>$400.00</td>
<td>$180.4K</td>
<td align="right">3</td>
<td>27</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$6.85</td>
<td>$6.55</td>
<td>$6.55</td>
<td>$332.50</td>
<td>$149.9K</td>
<td align="right">37</td>
<td>28</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$2.01</td>
<td>$1.87</td>
<td>$2.15</td>
<td>$342.50</td>
<td>$105.7K</td>
<td align="right">127</td>
<td>1.1K</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$161.9</td>
<td>$161.25</td>
<td>$161.25</td>
<td>$175.00</td>
<td>$96.7K</td>
<td align="right">112</td>
<td>11</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$7.1</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$400.00</td>
<td>$91.0K</td>
<td align="right">850</td>
<td>136</td>
</tr>
</tbody>
</table>
</p>
<h3>About Salesforce</h3>
<p>Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.</p>
<p>In light of the recent options history for Salesforce, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>With a trading volume of 2,523,597, the price of CRM is down by -1.41%, reaching $329.61.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>Expert Opinions on Salesforce</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $425.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Salesforce, maintaining a target price of $405.<br />
&#x2A; An analyst from Scotiabank persists with their Sector Outperform rating on Salesforce, maintaining a target price of $440.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Salesforce with a target price of $425.<br />
&#x2A; In a cautious move, an analyst from JMP Securities downgraded its rating to Market Outperform, setting a price target of $450.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Salesforce, maintaining a target price of $405. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Salesforce, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


What the Options Market Tells Us About Salesforce

<p>In the latest quarter, 7 analysts provided ratings for Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $74.29, along with a high estimate of $80.00 and a low estimate of $71.00. This current average reflects an increase of 2.23% from the previous average price target of $72.67. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844418_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Equity Lifestyle Props. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Anthony Hau</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$71.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Merrill Ross</td>
<td>Compass Point</td>
<td>Raises</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$76.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Wesley Golladay</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$77.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Peter Abramowitz</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$72.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Equity Lifestyle Props. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Equity Lifestyle Props compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Equity Lifestyle Props's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Equity Lifestyle Props's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ELS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Equity Lifestyle Props analyst ratings.</strong></a></p>
<h2>All You Need to Know About Equity Lifestyle Props</h2>
<p>Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.</p>
<h3>Unraveling the Financial Story of Equity Lifestyle Props</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Equity Lifestyle Props faced challenges, resulting in a decline of approximately <strong>-0.64%</strong> in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Real Estate sector.</p>
<p><strong>Net Margin:</strong> Equity Lifestyle Props's net margin excels beyond industry benchmarks, reaching <strong>22.62%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Equity Lifestyle Props's ROE excels beyond industry benchmarks, reaching <strong>5.78%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.47%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Equity Lifestyle Props's debt-to-equity ratio is notably higher than the industry average. With a ratio of <b>2.44</b>, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


The Analyst Verdict: Equity Lifestyle Props In The Eyes Of 7 Experts

<p>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) has been analyzed by 14 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Sage Therapeutics, presenting an average target of $11.43, a high estimate of $26.00, and a low estimate of $4.00. This current average represents a 32.76% decrease from the previous average price target of $17.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735844410_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Sage Therapeutics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$6.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$4.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$14.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$26.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Perform</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sage Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Sage Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>For valuable insights into Sage Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sage Therapeutics analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Sage Therapeutics</h2>
<p>Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.</p>
<h3>Breaking Down Sage Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Sage Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>337.08%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Sage Therapeutics's net margin excels beyond industry benchmarks, reaching <strong>-788.06%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Sage Therapeutics's ROE excels beyond industry benchmarks, reaching <strong>-15.86%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-14.18%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.02</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SAGE

Where Sage Therapeutics Stands With Analysts

<p><strong>Do Kwon</strong>, co-founder of Terraform Labs, the incubator of <strong>TerraUSD</strong> (CRYPTO: USTC) and <strong>Luna</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">LUNC</a>), is set to face criminal fraud charges in a U.S. court following his <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42709119/terra-luna-co-founder-do-kwon-to-be-extradited-to-the-us-report">extradition from Montenegro</a>.</p>
<p><strong>What Happened: </strong>Kwon is expected to appear before U.S. Magistrate Judge <strong>Robert Lehrburger </strong>in a Manhattan federal court on Thursday afternoon, <a href="https://www.scmp.com/news/world/united-states-canada/article/3293212/former-cryptocurrency-executive-do-kwon-appear-us-court-criminal-fraud-charges?module=perpetual_scroll_0&amp;pgtype=article">according</a> to the South China Morning Post.</p>
<p>Kwon has been charged with multiple counts of commodities fraud, conspiracy, securities fraud and wire fraud related to the collapse Luna and TerraUSD in 2022, which resulted in an estimated $40 billion loss.</p>
<p><strong>Why It Matters: </strong>The extradition marks the end of a prolonged legal battle involving competing requests from the U.S. and South Korea. </p>
<p>Montenegro Minister of Justice <strong>Bojan Božović</strong> ultimately authorized Kwon&#8217;s transfer to the U.S., citing factors such as the gravity of the alleged offenses and the sequence of extradition requests.</p>
<p>Kwon agreed to pay an $80 million civil fine in June 2024, having been banned from cryptocurrency transactions as part of a $4.55 billion settlement with the SEC. </p>
<p>He has denied any wrongdoing related to the charges.</p>
<p>The case has drawn significant attention in the crypto world, with the TerraUSD token experiencing a 4% surge following news of Kwon&#8217;s extradition.</p>
<p>Kwon&#8217;s legal troubles follow other high-profile, such as <strong>Sam Bankman-Fried</strong>&#8216;s <a href="https://www.benzinga.com/news/24/10/41141962/remember-sbfs-i-didnt-stash-billions-away-the-latest-ftx-repayment-update-may-have-other-ideas">conviction and sentencing</a>, and <strong>Alex Mashinsky</strong>&#8216;s <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42307121/celsius-network-founder-alex-mashinsky-pleads-guity-to-two-counts-of-fraud-including-manipulating-in-house-cryptos-price">guilty plea</a> related to the Celsius Network collapse.</p>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42771994/xrp-price-surges-9-what-is-going-on-with-ripple">XRP Price Surges 9%: What Is Going On With Ripple?</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Global

$LUNC

Terra Luna's Do Kwon To Face Criminal Fraud Charges In US

<p>Deep-pocketed investors have adopted a bullish approach towards Newmont (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NEM usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 31 extraordinary options activities for Newmont. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 77% leaning bullish and 16% bearish. Among these notable options, 9 are puts, totaling $287,714, and 22 are calls, amounting to $2,601,084.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $65.0 for Newmont over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In terms of liquidity and interest, the mean open interest for Newmont options trades today is 2412.25 with a total volume of 10,184.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Newmont's big money trades within a strike price range of $30.0 to $65.0 over the last 30 days.</p>
<h3>Newmont Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735843529_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/21/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$45.00</td>
<td>$320.0K</td>
<td>818</td>
<td>1.0K</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$9.05</td>
<td>$9.0</td>
<td>$9.05</td>
<td>$32.50</td>
<td>$270.5K</td>
<td>454</td>
<td>1</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$10.45</td>
<td>$10.35</td>
<td>$10.45</td>
<td>$30.00</td>
<td>$238.2K</td>
<td>55</td>
<td>229</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$9.05</td>
<td>$9.0</td>
<td>$9.05</td>
<td>$32.50</td>
<td>$193.6K</td>
<td>3.4K</td>
<td>231</td>
</tr>
<tr>
<td>NEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.55</td>
<td>$7.45</td>
<td>$7.55</td>
<td>$32.50</td>
<td>$189.5K</td>
<td>1.3K</td>
<td>253</td>
</tr>
</tbody>
</table>
</p>
<h3>About Newmont</h3>
<p>Newmont is the world's largest gold miner. It bought Goldcorp in 2019, combined its Nevada mines in a joint venture with competitor Barrick later that year, and also purchased competitor Newcrest in November 2023. Its portfolio includes 17 wholly or majority owned mines and interests in two joint ventures in the Americas, Africa, Australia and Papua New Guinea. The company is expected to produce roughly 5.5 million ounces of gold in 2024 from its core mines and 6.8 million in total. It is likely to sell a number of its higher cost, smaller mines accounting for 20% of forecast sales in 2024. Newmont also produces material amounts of copper, silver, zinc, and lead as byproducts. It had about two decades of gold reserves along with significant byproduct reserves at the end of December 2023.</p>
<p>Having examined the options trading patterns of Newmont, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Newmont Standing Right Now?</h3>
<ul>
<li>With a volume of 4,043,630, the price of NEM is up 3.05% at $38.35. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 49 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Newmont options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Decoding Newmont's Options Activity: What's the Big Picture?

<p>Deep-pocketed investors have adopted a bullish approach towards C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in AI usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for C3.ai. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 33% leaning bullish and 26% bearish. Among these notable options, 10 are puts, totaling $911,190, and 5 are calls, amounting to $225,320.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $65.0 for C3.ai during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for C3.ai's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of C3.ai's whale trades within a strike price range from $15.0 to $65.0 in the last 30 days. </p>
<h3>C3.ai 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735843524_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AI</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$2.07</td>
<td>$2.01</td>
<td>$2.01</td>
<td>$30.00</td>
<td>$341.6K</td>
<td>769</td>
<td>1.7K</td>
</tr>
<tr>
<td>AI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.85</td>
<td>$10.7</td>
<td>$10.77</td>
<td>$45.00</td>
<td>$112.9K</td>
<td>2.1K</td>
<td>763</td>
</tr>
<tr>
<td>AI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.95</td>
<td>$10.75</td>
<td>$10.83</td>
<td>$45.00</td>
<td>$99.6K</td>
<td>2.1K</td>
<td>105</td>
</tr>
<tr>
<td>AI</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.9</td>
<td>$10.75</td>
<td>$10.83</td>
<td>$45.00</td>
<td>$72.5K</td>
<td>2.1K</td>
<td>205</td>
</tr>
<tr>
<td>AI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$10.85</td>
<td>$10.75</td>
<td>$10.78</td>
<td>$45.00</td>
<td>$62.4K</td>
<td>2.1K</td>
<td>460</td>
</tr>
</tbody>
</table>
</p>
<h3>About C3.ai</h3>
<p>C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.</p>
<p>Following our analysis of the options activities associated with C3.ai, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of C3.ai</h3>
<ul>
<li>Trading volume stands at 2,261,773, with AI's price down by -0.41%, positioned at $34.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 55 days.</li>
</ul>
<h3>What Analysts Are Saying About C3.ai</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $42.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Piper Sandler has decided to maintain their Neutral rating on C3.ai, which currently sits at a price target of $42.<br />
&#x2A; In a cautious move, an analyst from JP Morgan downgraded its rating to Underweight, setting a price target of $28.<br />
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Hold rating on C3.ai with a target price of $40.<br />
&#x2A; An analyst from Northland Capital Markets has decided to maintain their Outperform rating on C3.ai, which currently sits at a price target of $45.<br />
&#x2A; Maintaining their stance, an analyst from JMP Securities continues to hold a Market Outperform rating for C3.ai, targeting a price of $55. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for C3.ai with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


What the Options Market Tells Us About C3.ai

<p>High-rolling investors have positioned themselves bullish on Dutch Bros (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in BROS often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for Dutch Bros. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 55% bullish and 22% bearish. Among all the options we identified, there was one put, amounting to $27,000, and 8 calls, totaling $494,725.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $35.0 to $60.0 for Dutch Bros over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In terms of liquidity and interest, the mean open interest for Dutch Bros options trades today is 398.25 with a total volume of 656.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Dutch Bros's big money trades within a strike price range of $35.0 to $60.0 over the last 30 days.</p>
<h3>Dutch Bros Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1735843518_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$18.0</td>
<td>$17.6</td>
<td>$18.0</td>
<td>$37.00</td>
<td>$161.9K</td>
<td>222</td>
<td align="right">100</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$20.3</td>
<td>$20.0</td>
<td>$20.1</td>
<td>$35.00</td>
<td>$60.3K</td>
<td>1.0K</td>
<td align="right">30</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$4.0</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$52.50</td>
<td>$55.3K</td>
<td>1.4K</td>
<td align="right">153</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.9</td>
<td>$5.4</td>
<td>$5.5</td>
<td>$57.50</td>
<td>$55.0K</td>
<td>81</td>
<td align="right">100</td>
</tr>
<tr>
<td>BROS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$4.8</td>
<td>$4.7</td>
<td>$4.8</td>
<td>$60.00</td>
<td>$47.9K</td>
<td>272</td>
<td align="right">100</td>
</tr>
</tbody>
</table>
</p>
<h3>About Dutch Bros</h3>
<p>Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies and other beverages. The company has two reportable operating segments company-operated shops and franchising and other.</p>
<p>Following our analysis of the options activities associated with Dutch Bros, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of Dutch Bros</h3>
<ul>
<li>Currently trading with a volume of 2,138,805, the BROS's price is up by 6.18%, now at $55.62. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 48 days.</li>
</ul>
<h3>Expert Opinions on Dutch Bros</h3>
<p>Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $61.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from UBS continues to hold a Buy rating for Dutch Bros, targeting a price of $65.<br />
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Dutch Bros, targeting a price of $60.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Dutch Bros, targeting a price of $58. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Dutch Bros with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BROS

Market Whales and Their Recent Bets on BROS Options

<p><strong>Goldman Sachs</strong> analyst Tina Hou maintained a Buy rating on <strong>Li Auto Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) with a <a target="_blank" href="https://www.benzinga.com/quote/LI/analyst-ratings" rel="noreferrer noopener">price target of $36</a>.</p>
<p>Li Auto is a leading pure New Energy Vehicle (NEV) player, with a 5% NEV market share in China as of the first quarter of 2024 (17% and 39% market share in China's premium PV and premium NEV market, respectively).</p>
<p>As Hou noted, the company will have the most potent model pipeline of 5 new launches and the most vigorous sales network expansion of 400 stores in 2024.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42767647/chinese-stocks-drop-as-manufacturing-growth-slows-and-geopolitical-tensions-hit" rel="noreferrer noopener">Chinese Stocks Drop As Manufacturing Growth Slows And Geopolitical Tensions Hit</a></em></p>
<p>The analyst expects the competitive positioning of Battery Electric Vehicle (BEV) models and deepening sales network to drive another leg of growth for Li Auto.</p>
<p>With continued scale economics and operating leverage, Hou expects Li Auto to deliver the fastest earnings growth and generate top-tier free cash flow among her China auto OEM coverage.</p>
<p>Over the past six months, Hou noted signs that Li Auto has not only caught up with industry leaders in terms of urban NOA (navigate on autopilot) performance but has also become one of the best in the market. The improvement has resulted in a higher take-rate of its Max version models and an improved vehicle gross margin.</p>
<p>Looking into 2025, the company expects to achieve L3 autonomous driving capability utilizing its current "End-to-End + VLM" architecture and MPI (mile per intervention) of 1 takeover per 500km.</p>
<p>With Li Auto's strengthening focus on AI and visible improvements in its urban NOA performance, Hou noted the company is well positioned to benefit from the ongoing intelligent driving trend, supporting volume growth with a better Max version blend, margin improvement, and ongoing BOM cost reduction.</p>
<p>Hou projected fiscal 2024 revenue of 144.13 billion Chinese yuan and EPS of 3.30 Chinese yuan.</p>
<p><strong>Price Action:</strong> LI stock is up 1.04% at $24.24 at last check Thursday.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42725756/xiaomi-evs-to-access-charging-networks-of-nio-xpeng-and-li-auto" target="_blank" rel="noreferrer noopener">Xiaomi Expands EV Charging Options, Partners with NIO, XPeng, and Li Auto for Greater Network Access</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Price Target

Reiteration

Goldman Sachs Sees Strong Upside In Li Auto on New Model Pipeline and Autonomous Driving Advances

<p>Despite ongoing legal challenges, <a target="_blank" href="https://www.benzinga.com/topic/tiktok" rel="noreferrer noopener">TikTok</a> content creators refuse to prepare for a potential U.S. ban on the app that helped them garner millions of followers in four years, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/tech/a-tiktok-ban-looms-creators-say-theyll-believe-it-when-they-see-it-6727dd67" rel="noreferrer noopener">reports</a>.</p>
<p>The ban, which will take effect on January 19, stems from a law requiring TikTok to be sold to a non-Chinese owner.</p>
<p>TikTok and its parent company, ByteDance lawyers, have appealed to the Supreme Court to halt the ban pending their appeal&nbsp;to a lower-court ruling.</p>
<p><strong><em>Also Read:</em></strong><em> <a target="_blank" href="https://www.benzinga.com/24/12/42658286/metas-ai-powered-ad-growth-and-expanding-user-base-drive-analyst-optimism" rel="noreferrer noopener">Meta User Base, AI-Powered Ad Growth Drive Analyst Optimism</a></em></p>
<p>A lot seems to be brewing in the social media landscape as President-elect Donald Trump prepares to take charge in January. Trump has fueled hope among TikTok supporters by urging the Supreme Court to delay the law&#8217;s implementation.</p>
<p>TikTok has become a critical platform for creators and advertisers, accounting for ~4% of the U.S. digital ad market, the WSJ cites eMarketer.&nbsp; &nbsp; &nbsp;&nbsp;TikTok, boasting 170 million U.S. users, estimated that creators could lose $300 million in monthly earnings upon a ban.</p>
<p>In 2020, then-President Donald Trump called the app&nbsp;a &#8220;national security&#8221; risk <a target="_blank" href="https://www.benzinga.com/government/20/09/17671544/judge-blocks-trump-order-on-tiktok-just-hours-before-ban-goes-into-effect" rel="noreferrer noopener">since&nbsp;it is owned by</a> a Beijing-based parent company.&nbsp;<strong>ByteDance Ltd.</strong>, which launched TikTok in 2018 after acquiring&nbsp;Shanghai-based video app Musical.ly for&nbsp;$1 billion,&nbsp;could gather data on Americans on behalf of Chinese authorities, he had said.</p>
<p>However, a federal judge has halted the Trump Administration&#8217;s ban on <strong>TikTok</strong>. Then, Trump forced a sale of TikTok to U.S. companies, with Bytedance still holding a majority stake.</p>
<p>Meanwhile, advertisers have contingency plans to redirect ad spending to platforms such as <strong>Meta Platforms Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Instagram and <strong>Alphabet Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube upon a TikTok ban.</p>
<p>Reportedly, ByteDance <a target="_blank" href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42725613/tiktok-parent-plans-7-billion-ai-push-with-nvidia-chips" rel="noreferrer noopener">plans to spend</a> $7 billion on <strong>Nvidia Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips outside China to accomplish its artificial intelligence ambitions, signifying growing ties between Chinese and U.S. companies despite the U.S. semiconductor embargo on China.</p>
<p>Recently, <strong>Amazon.Com Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)<strong> </strong>also tapped <strong>TikTok</strong> targeting $1 billion in sales boost through <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40294494/amazon-teams-up-with-tiktok-pinterest-for-shoppable-ads-analyst-sees-1b-payoff" rel="noreferrer noopener">in-app shopping ads</a>.</p>
<p>In July, Needham&#8217;s Laura Martin valued TikTok higher than Reels and Shorts backed by its <a target="_blank" href="https://www.benzinga.com/top-stories/24/07/39991984/tiktok-vs-reels-vs-shorts-analyst-sizes-up-short-form-video-platforms-on-valuation-and-monetization" rel="noreferrer noopener">revenue, active users</a> and engagement measures.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/12/42729529/social-media-stocks-react-as-trump-targets-censorship-and-delays-tiktok-ban" target="_blank" rel="noreferrer noopener">Trump Administration to Challenge Social Media Censorship, Setting Stage for Conflict with EU Regulations</a></strong></li>
</ul>
<p><em>Image via Shutterstock</em></p>


Government

Regulations

Tech

AMZN

GOOG

GOOGL

NVDA

TikTok Set For A Ban on Jan 19 By Law, But Trump Has Other Plans

Accustem Sciences

<p>US crude oil futures traded lower this morning on Thursday. Investors, meanwhile, focused on some notable insider trades.</p>

<p>When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.</p>

<p>Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"><em> Benzinga&#39;s insider transactions </em></a> platform.</p>

<h2><strong>Bluejay Diagnostics </strong></h2>

<ul>
	<li><strong>The Trade:</strong> <strong> Bluejay Diagnostics, Inc. </strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) Chief Financial Officer Kenneth Fisher <a href="https://www.benzinga.com/sec/insider-trades/"><em> acquired a total of 20,000 shares </em></a> at an average price of $0.99. To acquire these shares, it cost $19.8 thousand.</li>
	<li><strong>What&rsquo;s Happening:</strong> Bluejay Diagnostics recently posted a Q1 loss of $0.10 per share.</li>
	<li><strong>What Bluejay Diagnostics Does:</strong> Bluejay Diagnostics Inc develops, manufactures and markets innovative clinical diagnostic products that improve the quality of medical diagnoses by developing Point-of-Care tests that provide convenience, timeliness, compliance and low cost to physicians and patients in areas where timeliness of the initial triage assessment has a high impact on course of treatment.</li>
</ul>

<h2><strong>Rise Gold </strong></h2>

<ul>
	<li><strong>The Trade</strong>: <strong> Rise Gold Corp. </strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RYES#OTC">RYES</a>) Director Lawrence W. Lepard <a href="https://www.benzinga.com/sec/insider-trades/"><em> acquired a total of 216,500 shares </em></a> at an average price of $0.51. The insider spent around $110.59 thousand to buy those shares.</li>
	<li><strong>What&rsquo;s Happening</strong>: Rise Gold recently reported progress on Idaho-Maryland use permit.</li>
	<li><strong>What Rise Gold Does</strong>: Rise Gold Corp is a mineral exploration stage mining company and its primary asset is a major past producing Idaho-Maryland Gold Mine property near Grass Valley, California, United States.</li>
</ul>

<p><a href="https://www.benzinga.com/trading-ideas/long-ideas/22/04/26834505/executives-buy-around-413m-of-3-stocks"><em>Also check this: Executives Buy Around $413M Of 3 Stocks </em></a></p>

<p><em>Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>.</em></p>

<h2><strong>Augusta Gold </strong></h2>

<ul>
	<li><strong>The Trade</strong>: <strong> Augusta Gold Corp. </strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AUGG#OTC">AUGG</a>) Director Augusta Investments Inc <a href="https://www.benzinga.com/sec/insider-trades/"><em> acquired a total of 22,500 shares </em></a> at an average price of $1.14. To acquire these shares, it cost around $25.61 thousand.</li>
	<li><strong>What&rsquo;s Happening</strong>: The company&rsquo;s stock has gained 35% since the start of the year.</li>
	<li><strong>What Augusta Gold Does</strong>: Augusta Gold Corp is an exploration stage company. The company is primarily engaged in the acquisition and exploration of gold properties.</li>
</ul>

<h2><strong>Accustem Sciences </strong></h2>

<ul>
	<li><strong>The Trade</strong>: <strong> Accustem Sciences Inc. </strong> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ACUT#OTC">ACUT</a>) Director Gabriele M Cerrone <a href="https://www.benzinga.com/sec/insider-trades/"><em> acquired a total of 9,447 shares </em></a> at an average price of $1.43. The insider spent $13.49 thousand to buy those shares.</li>
	<li><strong>What&rsquo;s Happening</strong>: AccuStem recently reported a private placement of common stock.</li>
	<li><strong>What Accustem Sciences Does</strong>: Accustem Sciences Inc is a life sciences company dedicated to optimizing outcomes for all patients with cancer across the globe.</li>
</ul>
 

Comments

Accustem Sciences

News

Latest news for Accustem Sciences (OTC:ACUT) Stock

Thursday, April 28, 2022

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga